Inactive Instrument

AgeX Therapeutics, Inc.

Equities

AGE

US00848H2076

AGEX THERAPEUTICS, INC. : Other Events (form 8-K)

January 05, 2021 at 12:45 pm

Item 8.01 - Other Events

Effective January 1, 2021, AgeX relocated its principal offices to 1101 Marina Village Parkway, Suite 201, Alameda, California, following the December 31, 2020 expiration of the lease of its former office and laboratory facility. AgeX's new offices occupy 135 square feet of space in a building located in an office and research park. Base monthly rent is $947 for the one year lease term and also covers office furniture rental, janitorial services, utilities and internet service.

Latest news about AgeX Therapeutics, Inc.

Serina Therapeutics, Inc. completed the acquisition of AgeX Therapeutics, Inc. from a group of shareholders in a reverse merger transaction.	03-25	CI
AgeX Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-22	CI
AgeX Therapeutics, Inc. Appoints Steven Mintz as a Director, Member of Audit Committee, Compensation Committee and Nominating & Corporate Governance Committee	01-11	CI
Agex Therapeutics, Inc. Terminates Nafees Malik as Chief Operating Officer, Effective on December 27, 2023	12-01	CI
Pfizer Signs License Agreement With Serina Therapeutics to Gain Access to POZ Polymer Technology	11-17	MT
Earnings Flash (AGE) AGEX THERAPEUTICS Posts Q3 Revenue $67,000	11-14	MT
AgeX Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
AgeX Therapeutics, Inc. Announces Departure of Dr. Michael H. May as Director of the Company	08/09/23	CI
Serina Therapeutics, Inc. entered into a merger agreement to acquire AgeX Therapeutics, Inc. from shareholders in a reverse merger transaction.	29/08/23	CI
Earnings Flash (AGE) AGEX THERAPEUTICS Posts Q2 Revenue $9,000	14/08/23	MT
AgeX Therapeutics, Inc. Announces CEO Changes	14/08/23	CI
Agex Therapeutics, Inc. Appoints Jean-Christophe Renondin on the Board of Directors, and Member of Audit Committee, Compensation Committee, and as Chair of the Nominating and Corporate Governance Committee	14/08/23	CI
AgeX Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
AgeX Therapeutics Issues Preferred Shares to Juvenescence in Exchange for Debt Cancellation	25/07/23	MT
AgeX Therapeutics, Inc. announced that it has received $13.66 million in funding from Juvenescence Ltd.	06/06/23	CI
AgeX Therapeutics to Appeal NYSE American's Delisting Notice	23/05/23	MT
AgeX Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23	CI
AgeX Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	31/03/23	CI
Earnings Flash (AGE) AGEX THERAPEUTICS Posts Q4 Revenue $8,000	31/03/23	MT
AgeX Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	30/03/23	CI
AgeX Therapeutics, Inc. announced that it has received $10 million in funding from Juvenescence Ltd.	12/03/23	CI
AgeX Therapeutics, Inc. amended terms of the transaction	24/01/23	CI
Earnings Flash (AGE) AGEX THERAPEUTICS Reports Q3 Revenue $9,000	10/11/22	MT
Earnings Flash (AGE) AGEX THERAPEUTICS Reports Q3 Revenue $9,000	10/11/22	MT
Earnings Flash (AGE) AGEX THERAPEUTICS Reports Q3 Loss $-0.06	10/11/22	MT

Chart AgeX Therapeutics, Inc.

Duration

Period

More charts

Company Profile

AgeX Therapeutics Inc. is a biotechnology company. The Company is focused on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases. The Company's proprietary technology, based on telomerase-mediated cellular immortality and regenerative biology, allows utilizing telomerase-expressing regenerative pluripotent stem cells (PSCs) for the manufacture of cell-based therapies. Its cell-based therapeutic candidates in development are AGEX-BAT1 and AGEX-VASC1. AGEX-BAT1 is a cell therapy product candidate in the discovery stage of development utilizing PSC-derived brown adipocytes for the treatment of certain age-related metabolic disorders such as Type II (adult-onset) diabetes and obesity. AGEX-VASC1 is a cell-based therapy comprised of young regenerative vascular-forming cells. AGEX-VASC1 may restore vascular support in aged ischemic tissues such as in peripheral vascular disease and ischemic heart disease.

Sector

More about the company